Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility

C. Roland Wolf, C. A.Dale Smith, Alan C. Gough, Julie E. Moss, Katherine A. Vallis, Graham Howard, Frank J. Carey, Ken Mills, William Mcnee, James Carmichael, Nigel K. Spurr

    Research output: Contribution to journalArticle

    135 Citations (Scopus)

    Abstract

    There have been a series of reports on the association of a genetic polymorphism at the cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many of these reports have remained contradictory either because of small numbers of patients studied or because of the limitations and controversy surrounding the pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We have recently developed a DNA-based assay that will allow the unequivocal identification of poor metabolizers and have applied this to the study of 1635 patients with different forms of cancer. Out of 361 lung cancer patients studied no statistically significant change in the proportion of PMs relative to controls was found. However, a significant increase in the proportion of poor metabolizers or heterozygotes was seen in leukaemia, bladder cancer and melanoma patients. This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.

    Original languageEnglish
    Pages (from-to)1035-1038
    Number of pages4
    JournalCarcinogenesis
    Volume13
    Issue number6
    DOIs
    Publication statusPublished - 1 Jun 1992

    Fingerprint

    Cytochrome P-450 CYP2D6
    Neoplasms
    Neoplasm Genes
    Genetic Polymorphisms
    Heterozygote
    Urinary Bladder Neoplasms
    Carcinogens
    Cytochrome P-450 Enzyme System
    Melanoma
    Lung Neoplasms
    Leukemia
    Pharmacokinetics
    DNA
    Genes

    Cite this

    Wolf, C. R., Smith, C. A. D., Gough, A. C., Moss, J. E., Vallis, K. A., Howard, G., ... Spurr, N. K. (1992). Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 13(6), 1035-1038. https://doi.org/10.1093/carcin/13.6.1035
    Wolf, C. Roland ; Smith, C. A.Dale ; Gough, Alan C. ; Moss, Julie E. ; Vallis, Katherine A. ; Howard, Graham ; Carey, Frank J. ; Mills, Ken ; Mcnee, William ; Carmichael, James ; Spurr, Nigel K. / Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. In: Carcinogenesis. 1992 ; Vol. 13, No. 6. pp. 1035-1038.
    @article{2645bc43e75f4aa3a5120ef382b25d91,
    title = "Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility",
    abstract = "There have been a series of reports on the association of a genetic polymorphism at the cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many of these reports have remained contradictory either because of small numbers of patients studied or because of the limitations and controversy surrounding the pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We have recently developed a DNA-based assay that will allow the unequivocal identification of poor metabolizers and have applied this to the study of 1635 patients with different forms of cancer. Out of 361 lung cancer patients studied no statistically significant change in the proportion of PMs relative to controls was found. However, a significant increase in the proportion of poor metabolizers or heterozygotes was seen in leukaemia, bladder cancer and melanoma patients. This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.",
    author = "Wolf, {C. Roland} and Smith, {C. A.Dale} and Gough, {Alan C.} and Moss, {Julie E.} and Vallis, {Katherine A.} and Graham Howard and Carey, {Frank J.} and Ken Mills and William Mcnee and James Carmichael and Spurr, {Nigel K.}",
    year = "1992",
    month = "6",
    day = "1",
    doi = "10.1093/carcin/13.6.1035",
    language = "English",
    volume = "13",
    pages = "1035--1038",
    journal = "Carcinogenesis",
    issn = "0143-3334",
    publisher = "Oxford University Press",
    number = "6",

    }

    Wolf, CR, Smith, CAD, Gough, AC, Moss, JE, Vallis, KA, Howard, G, Carey, FJ, Mills, K, Mcnee, W, Carmichael, J & Spurr, NK 1992, 'Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility', Carcinogenesis, vol. 13, no. 6, pp. 1035-1038. https://doi.org/10.1093/carcin/13.6.1035

    Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. / Wolf, C. Roland; Smith, C. A.Dale; Gough, Alan C.; Moss, Julie E.; Vallis, Katherine A.; Howard, Graham; Carey, Frank J.; Mills, Ken; Mcnee, William; Carmichael, James; Spurr, Nigel K.

    In: Carcinogenesis, Vol. 13, No. 6, 01.06.1992, p. 1035-1038.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility

    AU - Wolf, C. Roland

    AU - Smith, C. A.Dale

    AU - Gough, Alan C.

    AU - Moss, Julie E.

    AU - Vallis, Katherine A.

    AU - Howard, Graham

    AU - Carey, Frank J.

    AU - Mills, Ken

    AU - Mcnee, William

    AU - Carmichael, James

    AU - Spurr, Nigel K.

    PY - 1992/6/1

    Y1 - 1992/6/1

    N2 - There have been a series of reports on the association of a genetic polymorphism at the cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many of these reports have remained contradictory either because of small numbers of patients studied or because of the limitations and controversy surrounding the pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We have recently developed a DNA-based assay that will allow the unequivocal identification of poor metabolizers and have applied this to the study of 1635 patients with different forms of cancer. Out of 361 lung cancer patients studied no statistically significant change in the proportion of PMs relative to controls was found. However, a significant increase in the proportion of poor metabolizers or heterozygotes was seen in leukaemia, bladder cancer and melanoma patients. This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.

    AB - There have been a series of reports on the association of a genetic polymorphism at the cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many of these reports have remained contradictory either because of small numbers of patients studied or because of the limitations and controversy surrounding the pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We have recently developed a DNA-based assay that will allow the unequivocal identification of poor metabolizers and have applied this to the study of 1635 patients with different forms of cancer. Out of 361 lung cancer patients studied no statistically significant change in the proportion of PMs relative to controls was found. However, a significant increase in the proportion of poor metabolizers or heterozygotes was seen in leukaemia, bladder cancer and melanoma patients. This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.

    UR - http://www.scopus.com/inward/record.url?scp=0026776502&partnerID=8YFLogxK

    U2 - 10.1093/carcin/13.6.1035

    DO - 10.1093/carcin/13.6.1035

    M3 - Article

    C2 - 1600608

    AN - SCOPUS:0026776502

    VL - 13

    SP - 1035

    EP - 1038

    JO - Carcinogenesis

    JF - Carcinogenesis

    SN - 0143-3334

    IS - 6

    ER -